ABBOTT LABORATORIES — Form 8-K
Filed August 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Abbott agreed to resolve the Gill case (originally $495M jury verdict in July 2024) and claims from approximately 2,000 additional infants for an aggregate $670 million. This settlement covers NEC-related claims but leaves roughly 1,700 lawsuits pending involving approximately 12,700 individual infants. Abbott explicitly states this is a compromise of disputed claims with no admission of liability, and reiterates that regulators and medical professionals recognize the products are safe.
Why this rating
Settlement of $670M is 0.29% of Abbott's $232B market cap—material in absolute terms but modest relative to company size. Largest exposure remains: ~12,700 pending claims. No business operations impaired.
See more from August 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.